TrialJAMA oncology2024

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

David Tougeron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.